Author Archives: HUAQUAN

Carlyle’s Abingworth Injects $210 Million into Gilead’s Trodelvy, Aiming to Revolutionize Cancer Treatment

Abingworth, backed by Carlyle, is set to invest up to $210 million in Gilead Sciences to enhance the utilization of Trodelvy, a cancer treatment drug. Since its U.S. approval in April 2020 for breast cancer treatment, Trodelvy’s potential expansion has been a focal point for Gilead, especially after its acquisition from Immunomedics in a $21 […]